Toxoplasmosis complications and novel therapeutic synergism combination of diclazuril plus atovaquone.

Citation data:

Frontiers in microbiology, ISSN: 1664-302X, Vol: 5, Issue: SEP, Page: 484

Publication Year:
2014
Usage 84
Downloads 50
Abstract Views 34
Captures 12
Readers 10
Exports-Saves 2
Citations 8
Citation Indexes 8
Repository URL:
https://uknowledge.uky.edu/internalmedicine_facpub/73
PMID:
25309522
DOI:
10.3389/fmicb.2014.00484
PMCID:
PMC4164033
Author(s):
Oz, Helieh S.
Publisher(s):
Frontiers Media SA
Tags:
Immunology and Microbiology; Medicine; toxoplasmosis; combination; diclazuril; atovaquone; synergism; obesity; Toxoplasma; gastroenteritis; Medicine and Health Sciences
article description
Toxoplasmosis is a major cause of foodborne disease, congenital complication, and morbidity. There is an urgent need for safe and effective therapies to encounter congenital and persisting toxoplasmosis. The hypothesis was: combination diclazuril plus atovaquone to exert a novel therapeutic synergy to prevent toxoplasmosis syndromes.